Lineage Cell Therapeutics, Inc. Common Stock (LCTX)
R&D Expenses
$4.77M
Quarterly · Period ending: · USD
LCTX R&D Expenses
Latest reported$4.77Mperiod ending
Latest reported$4.77Mperiod ending
LCTX Quarterly R&D Expenses ($0.00 → $4.77M)
Quarterly R&D Expenses
High-resolution chart · PNG
LCTX r&d expenses history
Quarterly · USD. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | R&D Expenses (USD) |
|---|---|
| 4,774,000 | |
| 4,234,000 | |
| 8,238,000 | |
| 3,271,000 | |
| 3,106,000 | |
| 3,114,000 | |
| 3,423,000 | |
| 3,171,000 | |
| 2,868,000 | |
| 2,988,000 | |
| 3,874,000 | |
| 3,741,000 | |
| 3,873,000 | |
| 4,185,000 | |
| 4,104,000 | |
| 3,592,000 | |
| 3,302,000 | |
| 2,988,000 | |
| 24,778,000 | |
| 2,811,000 | |
| 2,931,000 | |
| 3,394,000 | |
| 2,607,000 | |
| 3,566,000 | |
| 2,805,000 | |
| 3,339,000 | |
| 3,486,000 | |
| 4,266,000 | |
| 5,235,000 | |
| 4,961,000 | |
| 3,780,000 | |
| 4,882,000 | |
| 6,358,000 | |
| 5,935,000 | |
| 4,697,000 | |
| 6,562,000 | |
| 6,271,000 | |
| 6,494,000 | |
| 7,013,000 | |
| 6,422,000 | |
| 8,938,000 | |
| 13,734,000 | |
| 12,788,000 | |
| 11,433,000 | |
| 9,059,000 | |
| 9,323,510 | |
| 11,277,256 | |
| 8,836,341 | |
| 9,081,137 | |
| 8,405,393 | |
| 9,220,014 | |
| 6,441,462 | |
| 5,530,395 | |
| 5,395,488 | |
| 4,793,278 | |
| 4,545,470 | |
| 4,615,436 | |
| 4,178,781 | |
| 4,127,255 | |
| 3,445,708 | |
| 3,285,286 | |
| 2,855,669 | |
| 3,494,915 | |
| 1,808,357 | |
| 1,429,027 | |
| 1,159,951 | |
| 1,059,368 | |
| 744,201 | |
| 639,594 | |
| 525,824 | |
| 393,607 | |
| 548,478 | |
| 416,978 | |
| 347,151 | |
| 243,165 | |
| 170,382 | |
| 210,767 | |
| 343,550 | |
| 467,888 | |
| 304,562 | |
| 381,996 | |
| 265,932 | |
| 320,415 | |
| 401,144 | |
| 341,510 | |
| 462,608 | |
| 312,882 | |
| 305,626 | |
| 276,947 | |
| 227,806 | |
| 227,118 | |
| 239,760 | |
| 211,604 | |
| 224,536 | |
| 247,452 | |
| 251,994 | |
| 343,473 | |
| 260,571 | |
| 304,082 | |
| 236,481 |